Nirvana Reports Progress with Health Canada Dealer’s License Application and Facility Development
Vancouver, British Columbia–(Newsfile Corp. – April 26, 2022) – Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the “Company”), a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce an update on licensing and development for its Vancouver Lab facility.
Mr. Michael McCune, Vice President Operations commented, “We are pleased with the steady progress that our team is making on licensing. The application for the 29 different controlled substances will support all the projects that Nirvana’s researchers have in the development pipeline.”
“Our team’s focus on designing to the facility to the highest standard will ensure that our Research and Development projects meet the rigorous standards of Health Canada.”
The Company applied for a Dealer’s License from Health Canada in July of 2021. This License would permit research and development, manufacturing, import / export, sale to qualified investigators as well as sale to other Licensed Dealers in Canada for 29 different controlled substances, including novel compounds, consisting of different tryptamines, phenethylamines, ergolines and aryl cyclohexylamines. As part of its review, Health Canada has requested further detail on volumes of materials to be handled and produced within the facility.
To support this project, the company has engaged three leading firms with broad experience in this sector. CannDelta Inc., a scientific and regulatory consulting company based in Toronto, Ontario; Stratus Designs Ltd., a control systems specialist based in BC; and Orion GMP Solutions, a pharmaceutical process engineering specialist based in Rochester, Michigan.
About Nirvana Life Sciences Inc.
Nirvana Life Sciences Inc. has been founded with a simple objective of researching and developing non-addictive pain management and relapse prevention products that can provide healthier outcomes for patients who live with chronic pain and/or have battled with addiction. Nirvana believes that using naturally sourced psychedelics in novel formulations holds the promise of delivering non-addictive solutions that are effective in managing pain and addiction. Nirvana’s team, consisting of leading researchers from around the globe, will develop therapies that have the potential of freeing millions from addiction and saving society billions of dollars annually.
For further information:
Bruce Clark- CEO
info@nirvanalifescience.com
Phone: 604-401-8100
Forward-Looking Statements
This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward- looking statements”) within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company’s actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.